Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

Tamiko Tamanaha,Hisashi Makino,Cheol Son,Ryo Koezuka,Mayu Tochiya,Yoko Omura-Ohata,Tatsuya Takekawa,Masaki Matsubara,Michio Noguchi,Tsutomu Tomita,Kyoko Honda-Kohmo,Miki Matsuo,Emi Tateishi,Tetsuya Fukuda,Yoshihiro Miyamoto,Satoshi Yasuda,Kiminori Hosoda
DOI: https://doi.org/10.1007/s13300-024-01571-0
2024-04-06
Diabetes Therapy
Abstract:In patients with type 2 diabetes (T2D), treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.
endocrinology & metabolism
What problem does this paper attempt to address?